Vertex Pharmaceuticals Incorporated (VRTX)

397,48 -0,22 (-0,06 %) À la clôture : 04:00PM EDT

Vertex Pharmaceuticals Incorporated

50 Northern Avenue
Boston, MA 02210
United States
617 341 6100
https://www.vrtx.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 5 400

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Jeffrey Marc Leiden M.D., Ph.D.	Executive Chairman	95,02k	S.O.	1956
Dr. Reshma Kewalramani FASN, M.D.	CEO, President & Director	5,59M	3,86M	1973
Mr. Charles F. Wagner Jr.	Executive VP & CFO	2,12M	S.O.	1968
Mr. Stuart A. Arbuckle B.Sc.	Executive VP & COO	2,76M	3,21M	1966
Dr. David M. Altshuler M.D., Ph.D.	Executive VP & Chief Scientific Officer	2,17M	154,49k	1965
Ms. Kristen C. Ambrose CPA	Senior VP & Chief Accounting Officer	S.O.	S.O.	1977
Mr. Mike Tirozzi	SVP and Chief Information & Data Officer	S.O.	S.O.	S.O.
Susie Lisa	Senior Vice President of Investor Relations	S.O.	S.O.	S.O.
Mr. Jonathan Biller J.D.	Executive VP & Chief Legal Officer	S.O.	S.O.	1964
Ms. Nina Devlin	Senior VP & Chief Communications Officer	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Vertex Pharmaceuticals Incorporated en date du 1 avril 2024 est 8. Les scores principaux sont Audit : 9; Société : 7; Droits des actionnaires : 6; Compensation : 8.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.